Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer Academic Article uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Antineoplastic Agents
  • Kallikreins
  • Neoplasm Metastasis
  • Phenylthiohydantoin
  • Prostate-Specific Antigen
  • Prostatic Neoplasms, Castration-Resistant

abstract

  • Among men with nonmetastatic, castration-resistant prostate cancer with a rapidly rising PSA level, enzalutamide treatment led to a clinically meaningful and significant 71% lower risk of metastasis or death than placebo. Adverse events were consistent with the established safety profile of enzalutamide. (Funded by Pfizer and Astellas Pharma; PROSPER ClinicalTrials.gov number, NCT02003924 .).

publication date

  • June 28, 2018

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1800536

PubMed ID

  • 29949494

Additional Document Info

start page

  • 2465

end page

  • 2474

volume

  • 378

number

  • 26